BioCentury
ARTICLE | Clinical News

Alagebrium: Phase IIa discontinued

February 6, 2006 8:00 AM UTC

ALT withdrew its IND for the Phase IIa EMERALD trial of alagebrium for ED and discontinued development in the indication. FDA had placed the trial on clinical hold following a review of preclinical to...